Recombinant Human HLA-A*03:01&B2M&gp100 (ALLAVGATK) Monomer Protein
Beta LifeScience
SKU/CAT #: BLK-00104P-100UG

Human HLA-A*03:01&B2M&gp100 (ALLAVGATK) Monomer on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Recombinant Human HLA-A*03:01&B2M&gp100 (ALLAVGATK) Monomer Protein
Beta LifeScience
SKU/CAT #: BLK-00104P-100UG
Collections: Fc receptors, Recombinant proteins
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Human HLA-A*03:01&B2M&gp100 (ALLAVGATK) Monomer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus.It contains Gly25-Thr305 (HLA-A*03:01), Ile21-Met119 (B2M) and ALLAVGATK peptide. |
Purity | > 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
Accession | NP_002107.3(HLA-A*03:01)&P61769(B2M)&ALLAVGATK |
Target Symbol | HLA-A*03:01&B2M&gp100 (ALLAVGATK) Monomer |
Species | Human |
Expression System | HEK293 |
Tag | C-His-Avi |
Expression Range | Gly25-Thr305(HLA-A*03:01), Ile21-Met119(B2M) and ALLAVGATK peptide |
Mol. Weight | The protein has a predicted MW of 50.15 kDa. Due to glycosylation, the protein migrates to 51-60 kDa based on Tris-Bis PAGE result. |
Form | Lyophilized |
Formulation | Lyophilized from 0.22 um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
Endotoxin | Less than 1EU per ug by the LAL method. |
Storage | Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
Shipping | Shipped at ambient temperature. |
Gene Background | Immunization against the ALLAVGATK peptide may occur in melanoma patients and that the immunogenicity of this peptide is similar to that of the majority of melanoma differentiation antigens defined to date. Therefore, the use of ALLAVGATK in active immunotherapy for HLA-A3 melanoma patients, for whom no other immunogenic peptide has been so far described, remains a distinct possibility, providing that patients treated in vivo with this peptide develop a better in vitro response than already demonstrated for HLA-A2 epitopes generated from this same antigenic protein. |